Shamburg News · 8-K filed Oct 8, 2026, 9:24 AM EDT

Viatris to Acquire Pacira BioSciences for $36.50 Per Share in Cash via Tender Offer

PCRX · Pacira BioSciences, Inc.

  • Material agreement
  • Acquisition
  • Reg FD disclosure
  • Materiality: high

On October 8, 2026, Pacira BioSciences entered into a merger agreement with Viatris Inc. and Peach Purchaser Sub Inc. under which Viatris's subsidiary will commence a cash tender offer at $36.50 per share, to be followed by a second-step merger under Section 251(h) of the DGCL. The filing states the Company agreed to pay Viatris a $62.0 million termination fee in specified circumstances, and the Company Board unanimously recommended that stockholders tender their shares. A joint press release announcing the deal, citing an aggregate equity value of $1.65 billion, was furnished as Exhibit 99.1.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 7.01, 9.01, accession 0001104659-26-114571.

Written from the filing by Shamburg Markets. Figures are as reported by the company.